FindTrial
Sign In

A study to compare and know the beneficial role of intravenous magnesium sulfate vs placebo as an add on therapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease.

A prospective study to compare the efficacy of I.V Magnesium sulfate infusion vs. placebo, as an adjuvant to nebulised salbutamol in acute exacerbations of chronic obstructive pulmonary disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011354
Enrollment
60
Registered
2018-01-16
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Acute exacerbations of Chronic Obstructive Pulmonary Disease Health Condition 2: J441- Chronic obstructive pulmonary disease with (acute) exacerbation

Interventions

Intervention1: intravenous Magnesium sulfate 2g infusion in 100ml normal salineas an adjuvant to bronchodilators in acute exacerbations of COPD: 2g of IV magnesium sulfate infusion in 100ml normal sal

Sponsors

Kempegowda institute of medical sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: diagnosed with COPD grade 2 and grade 3 (GOLD criteria) presenting with symptoms of acute exacerbations.

Exclusion criteria

Exclusion criteria: subjects with severe COPD and requiring ventilation in next 2 hours. subjects with respiratory failure and altered sensorium. subjects with TB, Bronchiectasis, bronchial asthma. subjects with clinical evidence of CVA, CAD, Renal dysfunction, uncontrolled Diabetes Mellitus.

Design outcomes

Primary

MeasureTime frame
asses the efficacy of Magnesium sulfate infusion by monitoring the changes in PEFR from baselineTimepoint: asses the efficacy of Magnesium sulfate infusion by monitoring the changes in PEFR at 0,15,30 and 45 minutes from baseline—

Secondary

MeasureTime frame
to asses the safety and tolerability of IV magnesium sulfate based on adverse effects. To calculate the cost effectiveness of magnesium sulfateTimepoint: at the end of the study—

Countries

India

Contacts

Public ContactNeethi Shelly Selvam

Kempegowda institute of medical sciences

drgirish_k@rediffmail.com9980911060

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026